Patents by Inventor Ilaria Candiani

Ilaria Candiani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200325122
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 15, 2020
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria CANDIANI, Giovanni OTTAIANO, Attilio TOMASI
  • Patent number: 10738037
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 11, 2020
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria Candiani, Giovanni Ottaiano, Attilio Tomasi
  • Publication number: 20200246339
    Abstract: New N-(2,6-diethylphenyl)-8-({4-[4-(dimethyl amino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate of formula (II): Medicaments
    Type: Application
    Filed: June 28, 2018
    Publication date: August 6, 2020
    Inventors: Massimo ZAMPIERI, Marina CALDARELLI, Ilaria CANDIANI, Matteo D'ANELLO, Germano D'ARASMO
  • Patent number: 10519104
    Abstract: Carmustine may be safely and efficiently produced by reacting 2-chloroethylamine hydrochloride and 1,1?-carbonyldiimidazole to afford 1,3-bis(2-chloroethyl)-1-urea, followed by nitrosation to give the final product.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: December 31, 2019
    Assignee: NerPharMa S.r.l.
    Inventors: Attilio Tomasi, Ilaria Candiani, Francesco Corcella, Francesco Saverio Caldarelli
  • Publication number: 20190169173
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Application
    Filed: May 18, 2017
    Publication date: June 6, 2019
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria CANDIANI, Giovanni OTTAIANO, Attilio TOMASI
  • Publication number: 20170253557
    Abstract: Carmustine may be safely and efficiently produced by reacting 2-chloroethylamine hydrochloride and 1,1?-carbonyldiimidazole to afford 1,3-bis(2-chloroethyl)-1-urea, followed by nitrosation to give the final product.
    Type: Application
    Filed: February 28, 2017
    Publication date: September 7, 2017
    Applicant: NerPharMa S.r.l.
    Inventors: Attilio TOMASI, Ilaria Candiani, Francesco Corcella, Francesco Saverio Caldarelli
  • Patent number: 8648078
    Abstract: The present invention relates to novel crystalline, water-soluble salts of a plk inhibitor. Such crystal salts are for example L-tartrate, succinate, phosphate, mesylate, maleate, L-malate, hydrochloride, fumarate (half mole of counterion), fumarate, citrate (half mole of counterion), benzenesulfonate and L-aspartate (half mole of counterion). New crystal forms of the base as well as solvates and hydrates of such new salt forms, a process for their preparation, their utility in therapy and to the pharmaceutical compositions containing them are also claimed and described in the present application.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: February 11, 2014
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Massimo Zampieri, Italo Beria, Annalisa Airoldi, Ilaria Candiani, Riccardo Frigerio
  • Publication number: 20120157468
    Abstract: The present invention relates to novel crystalline, water-soluble salts of a plk inhibitor. Such crystal salts are for example L-tartrate, succinate, phosphate, mesylate, maleate, L-malate, hydrochloride, fumarate (half mole of counterion), fumarate, citrate (half mole of counterion), benzenesulfonate and L-aspartate (half mole of counterion). New crystal forms of the base as well as solvates and hydrates of such new salt forms, a process for their preparation, their utility in therapy and to the pharmaceutical compositions containing them are also claimed and described in the present application.
    Type: Application
    Filed: July 22, 2010
    Publication date: June 21, 2012
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Massimo Zampieri, Italo Beria, Annalisa Airoldi, Ilaria Candiani, Riccardo Frigerio
  • Publication number: 20060199849
    Abstract: The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is formed as an amorphous solid that is easily handled and particularly well suited to the formulation of pharmaceutical compositions.
    Type: Application
    Filed: February 27, 2006
    Publication date: September 7, 2006
    Applicant: Recordati Ireland Limited
    Inventors: Fabio Berlati, Amedeo Leonardi, Gianni Motta, Ilaria Candiani, Francesco Corcella
  • Patent number: 6906199
    Abstract: It is described a process for preparing, in high yields and purity and without the need of carrying out several steps and/or isolating many intermediates which could lead to undesired by-products, a distamycin derivative of formula wherein R is a bromine or chlorine atom; or a pharmaceutically acceptable salt thereof. The compounds of formula (I) are useful in therapy as antitumor agents.
    Type: Grant
    Filed: November 7, 2001
    Date of Patent: June 14, 2005
    Assignee: Pharmacia Italia S.p.A.
    Inventors: Francensco Caldarelli, Lucio Ceriani, Ilaria Candiani
  • Publication number: 20040077550
    Abstract: It is described a process for preparing, in high yields and purity and without the need of carrying out several steps and/or isolating many intermediates which could lead to undesired by-products, a distamycin derivative of formula 1
    Type: Application
    Filed: September 3, 2003
    Publication date: April 22, 2004
    Inventors: Francesco Caldarelli, Lucio Ceriani, Ilaria Candiani
  • Patent number: 6680327
    Abstract: Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture of forms I and VII of cabergoline in a solvent at a temperature above 30° C.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: January 20, 2004
    Assignee: Pharmacia Italia SpA
    Inventors: Ilaria Candiani, Raffaella Budelli, Marco Pandolfi, Mario Ungari
  • Publication number: 20030144516
    Abstract: Crystalline form VII of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise a slurry procedure using form I or mixture of forms I and VII of cabergoline in a solvent at a temperature above 30° C.
    Type: Application
    Filed: September 18, 2002
    Publication date: July 31, 2003
    Inventors: Ilaria Candiani, Raffaella Budelli, Marco Pandolfi, Mario Ungari
  • Patent number: 6420379
    Abstract: The present invention relates to alkynyl-substituted camptothecins of formula (I) wherein X, R1, R2 are as defined herein, and the pharmaceutically salts thereof. These compounds are useful in therapy as antitumor agents.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: July 16, 2002
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Ilaria Candiani, Angelo Bedeschi, Giuseppina Visentin, Maria Chiara Fagnola, Laura Capolongo
  • Patent number: 6403603
    Abstract: 9-Amino-20(S)-camptothecin (I) is prepared by reducing 12-nitro-20(S)-camptothecin (II); converting the resulting 12-amino-20(S)-camptothecin (III) into a compound of formula (IV) wherein X is a group which can be reductively removed; reacting the compound of formula (IV) with a nitrating agent, to obtain thereby the corresponding 9-nitro-20(S)-camptothecin compound of formula (V) substituted at the 12-position by the group X; reducing in a single step the compound of formula (V), so obtaining the 9-amino-20(S)-camptothecin of formula (I); or reducing the compound of formula (V), so obtaining the corresponding 9-amino-20(S)-camptothecin compound of formula (VI) substituted at the 12-position by the group X and reductively removing the X group from the compound of formula (VI), so obtaining 9-amino-20(S)-camptothecin.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: June 11, 2002
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Angelo Bedeschi, Walter Cabri, Ilaria Candiani, Franco Zarini
  • Patent number: 6211192
    Abstract: The present invention relates to alkynyl-substituted camptothecins of formula (I) wherein X, R1, R2 are as defined herein, and the pharmaceutically salts thereof. These compounds are useful in therapy as antitumor agents.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: April 3, 2001
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Ilaria Candiani, Angelo Bedeschi, Giuseppina Visentin, Maria Chiara Fagnola, Laura Capolongo
  • Patent number: 6093721
    Abstract: A water soluble camptothecin derivative which is 20(S)-7-ethyl-9(N-methyl-N-phenyl)amidino-camptothecin and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and a process for their preparation are described. The compound of the invention and its pharmaceutically acceptable salts are useful antitumor agents and are further charactcrised by having a remarkable therapeutic index.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: July 25, 2000
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Angelo Bedeschi, Walter Cabri, Ilaria Candiani, Laura Capolongo
  • Patent number: 5998426
    Abstract: The present invention relates to 9-amino-10-(1-naphthylsulfonyloxy)-20(S)-camptothecin, 9-amino-10-phenylsulfonyloxy-20(S)-camptothecin, 7-ethyl-9-amino-10-(p-toluensulfonyloxy)-20(S)-camptothecin, their pharmaceutically acceptable salts, a process for their preparation, pharmaceutically compositions comprising them and their use as antitumor agents.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: December 7, 1999
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Angelo Bedeschi, Walter Cabri, Ilaria Candiani, Franco Zarini, Sergio Penco
  • Patent number: 5990120
    Abstract: The present invention relates to novel hexacyclic camptohecin analogues, having a five-membered aza-heterocycle fused to ring (A) of camptothecin at positions 9 and 10. Such compounds possess high antitumor activity by inhibition of topoisomerase (I).
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: November 23, 1999
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Angelo Bedeschi, Ilaria Candiani, Franco Zarini
  • Patent number: 5916897
    Abstract: The present invention relates to compounds of the following formulas: ##STR1## which are endowed with antitumor activity. The invention also relates to methods of treating tumors using these compounds.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: June 29, 1999
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Walter Cabri, Ilaria Candiani, Franco Zarini, Angelo Bedeschi, Sergio Penco